NCT00088998View on ClinicalTrials.gov

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

December 31, 2010

Conditions
Breast Cancer
Interventions
BIOLOGICAL

bevacizumab

DRUG

capecitabine

DRUG

docetaxel

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00088998 - Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter